

# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines)

Fax: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com Website: www.aartidrugs.com

#### AARTI DRUGS LIMITED

_	STATEMENT OF AUDITED FINANCIAL R		_			Rs. In Lacs excer	s Ended	Year Ended
,	RT I		Quarter Ended			Milite Motitals Cire-		31st Mar 2012
<del></del>			31=1 Dec 2012	30th Sept 2012	3121 Dec 2011	31st Dec 2012	(Audited)	(Audited)
	Particulare	<u> </u>	(Audited)	(Audited)	(Audited)	(Audited)	(Addition)	
٠						1	i	
		1	Į.			24.747	47,431	69,918
•	Income from Operations		21,273	23,266	16,394	64,927	2,664	3,992
•	(a) Gross Sales / Income from Operations		1,424	1,633	885	4,461		65,926
	Less : Excise Duty & Sales Tax	Į	19,849	21.634	15,5QB	60,456	44,767	00,020
	(a) Net Sales / Income from Operations		1,,,,,,,,,			]		610
	(Net Of Excise Duty & Sales Tax)		65	6	3_	73	9	66,536
	(d) Other Operating Income	Į.	19,913	21,640	15,511	60,539	44,776	
	Total Income from operations (net)	+	19,510			\ \ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		l
	Total inventor	- 1	Į.		ļ	\ 1		29 414
	2 Expenditure	l	11,255	14,444		ገሮ በፕብ	77 155 5,582	38,414 7,336
	(a) Cost of materials consumed	Į	2,161	2,387	1,669	6,486	(1,871)	(92
	(b) Purchase of stock-in-trade	l	(412)	(648)	353	(2,071)	(1,871)	,
	(c) Changes in Inventories of finished goods.		,				1,617	2,483
	work-in-progress and stock-in-trade		774	667	555		1,520	2,422
	(d) Employee benefits expense		654	840	524		1	10,365
	(e) Depreciation and Americation Expense		3,157	3,191	2,502		7,373 41,356	80.93
	(f) Other expenses		17,590	19,323	14.263	53,955	41,350	
	Total expenses							
	3 Profit from Operations before Other Income,			2,317	1,248	6,585	3,420	5,609
	finance costs and exceptional items	(1-Z)	2,324	2,317	1,	_   _	-	_
	1		ì	2,317	7 1.248	6,585	3,420	5,80
	4 Other Income 5 Profit from ordinary activities before finance cost		2,324	2,317	( )	-		1
1		(3+4)			57-	4 2,048	1,432	2,25
	and exceptional items		749	660	91.		1	
	B Finance costs (interest)					4 4,537	1,986	3,33
	7 Profit from ordinary activities after finance cost	(5-6)	(5-6) 1,57	4 1,65	57   67	74 4.537	.,22	11
l	but before Exceptional Items	, .		<u>-L</u>		4 4,53	1,980	3,22
	8 Exceptional Items	(7-8)	1,574					
l	9 Profit from Ordinary Activities before Tax	•	480				'	1
	10 Tax Expenses (Includes)		400		- I	- 1	<b>'</b> ]	- 1
ļ	Provision for Taxation		80	o <u> </u>	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	4 22	<del>`                                    </del>	
	Provision for Deferred Taxation	(9-10)	1,094	4 1,16				
	11 Net profit from ordinary Activities after Tax	(5-,5)	1,21		1,2	1,21	1 1,21	18,4
	12 Paid-up Equity Share Capital of Rs.10/- each.		,,		-	-	*	10,4
	13 Cesanies & Surplus (excluding revaluation reserves)			1	1		_	
)	14 Earning per share (of Rs. 10 /- each) (not ennualised)		9.0	4 9.4	59 3.1	97 25.9	5 11.8	17.
	Basic & Dilinted		1	.		1		



## **Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

Ground Floor, Plot No. 109-D, Road No. 43, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines)

Fax: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com Website: www.aartidrugs.com

5,188,057 42.95	5,269,845 43,52	5,469,811 45,17	5,188,057 42.85	5,489,811 45,17	8,379,245 44,43
Nil	Nil	Nu	Mil	NII	Nil Nil
Mil	MII	Mil	Nif	Nii	Nil
6,920,493 100	<b>6,838,90</b> 5 100	6,638,739 100	6,920,493 100	6,636,739 100	6,729,305 100
57.15	56.48	54,83	67.15	54.83	55.5
Otr ended 31st Dec. 2012					
0 2					
2					
	42.85 Nil Nil Nil 6,920,493 100 57,15  Qtr ended 31st Dec, 2012 0 2 2	42.85 43.52  Nil	5,188,057 42,85 43,52 45,17  Nii Nii Nii Nii Nii Nii Nii Nii Nii Ni	5,188,057	5,188,057

The above results for the quarter and nine months ended 31st December, 2012 have been reviewed by the Audit Committee and taken on record by the

Board of Directors at their meeting held on 8th February, 2013.

Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business. The Board of Directors have declared 2nd Interim Dividend of Rs.3/- per equity shares of Rs. 10/- each amounting to Rs, 36325850/- and 12th February, 2013 has been fixed as record date for the payment of said interim dividend.

Figures for the previous period riske ocen regrouped or realizinged wherever riscospacity.

Figures for the quarter and nine months ended 31st December, 2011 do not reflect effect of Amalgamation of Erstwhile Suyash Laboratories Limited with the Figures for the previous period have been regrouped or rearranged wherever necessary. Company and to that extent they are not comparable.

For and on behalf of the Board For AARTI DRUGS LIMINED

Place : Mumbai

Date: 6th February, 2013

MR. HARSHIT M. SAVLA (JT. MANAGING DIRECTOR)

### PARIKH JOSHI & KOTHARE (Regd.)

CHARTERED ACCOUNTANTS

49/2341, M. H. B. Colony, Gandhi Nagar, Bandra (East), Mumbai 400 051.

Tele: 2645 1439/2651 5396 Fax: 91-22-2645 5867 Email: pjkbandra@yahoo.co.in

#### Auditor's Report On Quarterly Financial Results and Year to Date Results of AARTI DRUGS LTD Pursuant to the Clause 41 of the Listing Agreement

Board of Directors of AARTI DRUGS LTD

We have audited the quarterly financial results of AARTI DRUGS LTD for the quarter ended 31st December 2012 and the year to date results for the period 1st April 2012 to 31st December 2012, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

are presented in accordance with the requirements of clause 41 of the Listing Agreement in (i)

give a true and fair view of the net profit and other financial information for the quarter ended 31st December 2012 and the year to date results for the period 1st April 2012 to 31st December (ii) 2012.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

MUMBAI

For PARIKH JOSHI & KOTHARE CHARTERED ACCOUNTANTS Firm Registration No.: 107547W

CA TEJAS PARIKH

**PARTNER** M.No. 123215

Mumbai, Dated: February 6th, 2013